NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Gout Arthritis Clinical Trial

— ActiNG  

Official title:

NLRP3 Inflammasome Activation Among Patients During Acute Gout Flares

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05744297
• Other study ID #: ActiNG
• Status: Recruiting
• Start date: April 28, 2023
• Est. completion date: October 2023

Study information

• Verified date: February 2023
• Source: Centre Hospitalier Saint Joseph Saint Luc de Lyon
• Contact: Julien Seiller, MD
• Phone: 478 617 757
• Email: jseiller[@]chsjsl.fr
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Gout is a chronic joint disease associated with deposition of monosodium urate crystals, as a consequence of hyperuricemia. Gout is an intermittent flaring condition and acute gout flares are driven by NLRP3 inflammasome and IL1-beta production.

However pathogenesis of acute gout flares remains poorly known in vivo in human.

The aim of this study is to evaluate NLRP3 inflammasome activation in vivo in patients cells during acute gout flares.

Description:

Blood and synovial fluid will be obtained from remainder of patients' samples during an acute gout flares. White blood cells will be isolated and NLRP3 inflammasome activation will be assessed. Then, NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: October 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hospitalization for acute gout flare confirmed by joint fluid analysis or Nijmegen score > 8

• Aged > 18

Exclusion Criteria:

• Gout treatment already started

• Inflammatory Arthritis other than Gout Arthritis

• Pregnant or breast feeding women

• Patient protected by law

Related Conditions & MeSH terms

• Gout
• Gout Arthritis

Locations

Country	Name	City	State
France	Centre Hospitalier Saint Joseph Saint Luc	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NLRP3 inflammasome activation in white blood cells.	White blood cells will be isolated from blood sample and NLRP3 inflammasome activation will be assessed by flow cytometry.	Patient admission at hospital
Secondary	NLRP3 inflammasome activation in synovial cells.	Nucleated cells will be isolated from synovial fluid sample and NLRP3 inflammasome activation will be assessed by flow cytometry.	Patient admission at hospital
Secondary	Effects of NLRP3 inflammasome inhibitors on proportion of NLRP3 inflammasome activation in white blood cells/synovial cells	NLRP3 inflammasome inhibitors will be tested on cells with NLRP3 inflammasome activity in blood or synovial fluid.	up to 7 days after analysis of NLRP3 activity